Difference between revisions of "Category:RANK ligand inhibitors"
Jump to navigation
Jump to search
(Created page with "A class of drugs that inhibit the receptor activator of nuclear factor kappa-B ligand (RANKL). Currently Denosumab (Xgeva) is the only FDA-approved drug in this class.") |
m |
||
| Line 1: | Line 1: | ||
A class of drugs that inhibit the receptor activator of nuclear factor kappa-B ligand (RANKL). Currently [[Denosumab (Xgeva)]] is the only FDA-approved drug in this class. | A class of drugs that inhibit the receptor activator of nuclear factor kappa-B ligand (RANKL). Currently [[Denosumab (Xgeva)]] is the only FDA-approved drug in this class. | ||
| + | |||
| + | [[Category:Supportive medications]] | ||
Revision as of 12:48, 21 July 2017
A class of drugs that inhibit the receptor activator of nuclear factor kappa-B ligand (RANKL). Currently Denosumab (Xgeva) is the only FDA-approved drug in this class.
Pages in category "RANK ligand inhibitors"
This category contains only the following page.